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following either intravenous (n¼2) or subcutaneous (n¼2)
injection of cells as well as following skin graft rejection.
These results suggest that exposure to donor cells
following reduced intensity conditioning can result in
robust immune modulation of antibody responses to
allogeneic cells. B cell unresponsiveness is stable and does
not depend on persistence of unresponsiveness at the T
cell level or the persistence of donor cells. We speculate
that this mechanism of immune modulation of B cell
responses by allogeneic cells may play an important role
in facilitating induction of transplantation tolerance
through HCT.355
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Graft-versus-host disease (GVHD) remains a frequent
complication of hematopoietic cell transplantation (HCT)
with skin being a principal target organ. Murine models
have provided some insight into the mechanisms of this
complex disease process. However, mouse skin differs
from human skin, and results of studies in rodents may
not translate well to the clinic. The pig is a well-
recognized animal model for preclinical studies of skin
including dermal toxicology, transdermal drug delivery
and wound healing. Unlike skin of rodents, dogs or non-
human primates, porcine skin is similar to human skin
in terms of structure of epidermal rete ridges, hair
follicle structure and density, and presence of sweat
glands and subcutaneous fat. Because of the similarities
of pig skin to human skin and availability of swine with
deﬁned MHC genes, MGH miniature swine provide
a valuable pre-clinical model of HCT for studies of graft-
versus-host disease. HCT between MHC matched or
mismatched animals can be performed to mimic clinical
HCT scenarios with outcomes that closely resemble
those observed in human HCT recipients. With myeloa-
blative conditioning, HCT across MHC barriers is most
often fatal, with animals developing severe grade III-IV
GVHD involving the gastrointestinal tract (GI), liver and
skin. We have developed a comprehensive GVHD scoring
system for pigs which parallels that used clinically (see
chart). Unlike rodent models, miniature swine provide
an opportunity to perform extended longitudinal
studies, since multiple tissue biopsies can be taken
without the need to sacriﬁce the animal. Given the
similarities of GVHD in pigs and humans, we hope that
the utilization of the pig and scoring system facilitates
scientiﬁc discourse between the laboratory and the
clinic. We anticipate that results of swine studies will be
applicable to the development of new strategies to
improve GVHD identiﬁcation and treatment in clinical
HCT scenarios.356
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Background: Allogeneic HSCT from an HLA-matched sibling
donor is the recommended treatment approach in patients
with SAA, at least up to the age of 40 years. Cyclophospha-
mide (Cy)-ATG is the standard, non-myeloablative condi-
tioning regimen, while BM stem cells are the preferred
source of engraftment.
Aims:We have already published our data regarding the use
of PBSCs in patients with SAA conditioned with the Fludar-
abine (Flu)-Cy regimen (EBMT, Czech Republic 2005, Poster
Abst # 782 / CBMTG, Montreal 2008, oral Abst # 02). In this
single arm prospective study, we investigated the use of
FlueCy to allograft SAA patients >20 years old, using PBSCs.
Patients & methods: In the time period between May 2003
and December 2009, 53 heavily pre-transfused SAA patients
received allogeneic HLA- identical sibling PBSCs at the BMT
unit of Nasser institute, Cairo, Egypt. All patients were above
the age of 20 years (range 21- 41 years, mean 27 years). The
regimen consisted of Flu at a total dose ranging from 75mg-
120mg/ m2, and a total Cy dose of 200mg/kg. Our primary
endpoints were incidence and severity of chronic GVHD, as
well as DFS & OS. Cyclosporine & Methotrexate were used for
GVHD prophylaxis.
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106 /kg recipient weight. All patients engrafted rapidly at
a median rate of 15 days for neutrophils and 16 days for
platelets. Although the total incidence of cGVHD was 43%,
only 17% had extensive cGVHD, and the remaining 26% had
the limited form which was very well controlled under
a small-dose of immuno-suppressive therapy. By sub-group
analysis, we found that the vast majority of patients with
extensive cGVHD received the initial lower dose of Flu (75mg/
m2), and half of them were >30 years old. Since then, we've
standardized the dose to be 120mg/m2. At a follow up period
of up to 9 years (median 5.9 years), both DFS &OSwere 79.2%.
Conclusion: Allografting SAA patients with PBSCs, using the
Flu-Cy regimen has a signiﬁcantly lower cost, with excellent
tolerability, andpromisingoutcomeregardingengraftment,DFS
& OS. The incidence of cGVHD can be considered acceptable,
putting in mind the higher patients’ age and the initial lower
dose of Flu that we've used. However, this approach deﬁnitely
needs a larger cohort of patients to be randomly compared to
the standard Cy-ATG regimenwith the use of BM cells.357
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Allogeneic hematopoietic cell transplantation (Allo-
HSCT) has proven to have curative potential for myelodys-
plastic syndrome (MDS). However, relapse post HSCT
continues to be a problem. Pre-HSCT cytoreduction with
either intensive chemotherapy or hypomethylating agents
has been used with limited data on pre- or post-HSCT
outcomes. In this report, we evaluated the impact of pre-
transplant therapy on post-HSCT outcomes including overall
survival (OS) and Progression Free Survival (PFS).
Methods: We retrospectively reviewed 31 patients who
underwent allo-HSCT forMDS in our center between 1997 and
2012.Primaryobjectivewas to study the impactof therapypre-
HSCT on HSCT outcome. Demographics, disease-related and
transplant-relatedvariableswere collected. PFSwasdeﬁned as
the time from HSCT to the time of progression, death or last
contact whichever occurred ﬁrst. OS was deﬁned as the time
fromHSCTto the timeofdeathor last contact. Thedistributions
of PFS and OS were estimated by the Kaplan-Meier method.
The log-rank test was used to compare the survival distribu-
tions between the twogroups. Regression analyses for survival
data used Cox proportional hazards model.
Results:Median age at HSCT was 58 years. Median time from
diagnosis to HSCTwas 145 days. Of the 31 patients, 38.8% had
poor cytogenetic abnormalities. Conditioning regimen used
was high-dose in 71% or a reduced-intensity in 29%. 18/31
patients (58.1%) received therapy before HSCT. Intensive
therapy with cytarabine was used in 3 patients while non-
intensive therapy, with hypomethylating agents, median of 4
cycles, were used in 11 patients, Thalidomide or Lenalido-
mide in 3 patients and hydroxyurea in 1.13/31 (41.9%) did not
get any therapy prior to HSCT.
On univariate analysis, the treatment prior to HSCT had
adverse impact on PFS and OS (HR¼2.8, P ¼ .0404 and
HR¼2.8, P ¼ .0387 respectively). In multivariate models,
treatment prior to HSCT still emerged as a signiﬁcant
predictor of poor PFS and OS (HR¼6.6, P¼ .0070 and HR¼8.1,P¼ .0037 respectively) after adjusting for age, gender andWHO
classiﬁcation-based Prognostic Scoring System. There was no
statistical signiﬁcant difference in the change inpercentage of
blasts at diagnosis and just before transplant for those who
received therapy compared to those who did not (P ¼ .5496).
Conclusion: In this small cohort from a single center, the
results are not in favorofMDSpatients receiving therapyprior
to HSCT. Prospective study with larger cohort should be
conducted to address this issue and taking into consideration
disease characteristics in patients who may and may not
beneﬁt from pre-transplant therapy. As recently published
approximately 85% of bone marrow cells are clonal in MDS
regardless of blast count (Walter et al. NEJM 2012)whichmay
explain our result of no difference in blast percentage before
or after therapy and should not be used as a surrogatemarker.358
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Background: Invasive pulmonary aspergillosis (IPA) remains
a signiﬁcant cause of infectious morbidity and mortality in
hematopoietic cell transplant (HCT) recipients. The serum
and BAL galactomannan (GM) index are widely used myco-
logic criteria for the diagnosis of IPA; however, their prog-
nostic value at the time of diagnosis is poorly deﬁned. It
remains unclear whether IPA patients with a positive serum
or BAL GM index have different clinical outcomes than IPA
patients with a negative GM index in the corresponding
compartment, and whether higher GM index cut-off levels
correlate with poor outcome. In this study, we examined the
prognostic value of quantitative aspects of both the serum
and BAL GM index at the time of IPA diagnosis.
Methods: We retrospectively analyzed a cohort of 100 adult
patients with probable IPA (per 2008 revised EORTC criteria)
diagnosed in 2004-2010 within 100 days after a ﬁrst allo-
geneic HCT. All subjects had a chest CT, a serum GM, and
a BAL GM index performed at the time of IPA diagnosis. We
